Polymorphism and solvatomorphism 2008

Journal of Pharmaceutical Sciences

Volumn 99, Issue 9, 2010, Pages 3648-3664

  Brittain, Harry G ^a  

^a Center for Pharmaceutical Physics   (United States)

Author keywords

Crystal structure; Formulation; Hydrates solvates; Polymorphism; Preformulation; Transformation

Indexed keywords

1 METHYL 2 PYRROLIDINONE; 2 PROPANOL; ACETIC ACID; CAFFEINE; CARBAMAZEPINE; DIOXANE; FELODIPINE; FLUFENAMIC ACID; GABAPENTIN; GRISEOFULVIN; IBUPROFEN; INDOMETACIN; MEFENAMIC ACID; N,N DIMETHYLACETAMIDE; NIFEDIPINE; NITROMETHANE; ORGANIC COMPOUND; OXYBUPROCAINE; PARACETAMOL; PREDNISOLONE; RIFAXIMIN; SPARFLOXACIN; SULFAGUANIDINE; SULFATHIAZOLE; TEGASEROD; TERBUTALINE SULFATE; THEOPHYLLINE; TRIFLUOROACETIC ACID; UNINDEXED DRUG; VENLAFAXINE;

ANALYTIC METHOD; CHEMICAL REACTION; CRYSTAL STRUCTURE; DRUG FORMULATION; DRUG ISOLATION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; POLYMORPHISM; REVIEW; SOLVATOMORPHISM; SPECTROSCOPY; THERMAL ANALYSIS; X RAY DIFFRACTION;

EID: 77956356726     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21966     Document Type: Review

References (227)

1. Byrn SR, Pfeiffer RR, Stowell JG. 1999. Solid state chemistry of drugs, 2nd edition. West Lafayette: SSCI Inc.
2. Brittain HG. 1999. Polymorphism in pharmaceutical solids. New York: Marcel Dekker.
3. Bernstein J. 2002. Polymorphism in molecular crystals. Oxford: Clarendon Press.
4. Hilfiker R. 2006. Polymorphism in the pharmaceutical industry. Weinheim: Wiley-VCH.
5. Brittain HG, editor. 2005. Polymorphism and solvatomorphism 2004. In: Profiles of drug substances, excipients, and related methodology, Vol. 32. Amsterdam: Elsevier Academic Press. pp 263-283.
6. Brittain HG. 2007. Polymorphism and solvatomorphism 2005. J Pharm Sci 96:705-728.
7. Brittain HG. 2008. Polymorphism and solvatomorphism 2006. J Pharm Sci 97:3611-3636.
8. Brittain HG. 2009. Polymorphism and solvatomorphism 2007. J Pharm Sci 98:1617-1642.
9. Vishweshwar P, McMahon JA, Bis JA, Zaworotko MJ. 2006. Pharmaceutical cocrystals. J Pharm Sci 95:499-516.
10. Aakeröy CB, Salmon DJ. 2005. Building co-crystals with molecular sense and supramolecular sensibility. CrystEngComm 7:439-448.
11. Adeyeye MC, Brittain HG. 2008. Preformulation in solid dosage form development. New York: Informa Healthcare Press.
12. Desiraju GR. 2008. Polymorphism: The same and not quite the same. Cryst Growth Des 8:3-5.
13. Nangia A. 2008. Crystal Engineering: Inclusion compounds, molecular networks, cocrystals, and polymorphs. Cryst Growth Des 8:1079-1081.
14. Weng ZF, Motherwell WDS, Allen FH, Cole JM. 2008. Conformational variability of molecules in different crystal environments: A database study. Acta Cryst B64:348-362.
15. Bernstein J, Dunitz JD, Gavezzotti A. 2008. Polymorphic perversity: Crystal structures with many symmetry-independent molecules in the unit cell. Cryst Growth Des 8:2011-2018.
16. Altonen J, Gordon KC, Strachan CJ, Rades T. 2008. Perspectives in the use of spectroscopy to characterize pharmaceutical solids. Int J Pharm 364:159-169.
17. McGoverin CM, Rades T, Gordon KC. 2008. Recent pharmaceutical applications of Raman and Terahertz spectroscopies. J Pharm Sci 97:4598-4621.
18. 35Cl NMR to the structural characterization of hydrochloride pharmaceuticals and their polymorphs. J Am Chem Soc 130:11056-11065.
19. Giron D. 2008. Monitoring polymorphism of drugs, an ongoing challenge: Part 1. Am Pharm Rev 11:66-71;
20. Part 2, Am Pharm Rev 11:386-390.
21. Barnes S, Gillian J, Diederich A, Burton D, Ertl D. 2008. In process monitoring of polymorphic form conversion by Raman spectroscopy and turbidity measurements. Am Pharm Rev 11:80-85.
22. Sieger P. 2008. Choosing the right solid form depending on the dose and the route of application. Am Pharm Rev 11:28-32.
23. Bak A, Cooke M, Kleppe M. 2008. Water environment affects hydration and dehydration behavior of pharmaceutical compounds. Am Pharm Rev 11:116-120.
24. Nangia A. 2008. Conformational polymorphism in organic crystals. Acc Chem Res 41:595-604.
25. Mitchell-Koch KR, Matzger AJ. 2008. Evaluating computational predictions of the relative stabilities of polymorphic pharmaceuticals. J Pharm Sci 97:2121-2129.
26. Martín-Islán AP, Martín-Ramos D, Sainz-Díaz CI. 2008. Crystal structure of minoxidil at low temperature and polymorph prediction. J Pharm Sci 97:815-830.
27. Deij MA, van Eupen J, Meekes H, Verwer P, Bennema P, Vlieg E. 2008. Experimental and computational morphology of three polymorphs of the free base of Venlafaxine: A comparison of morphology prediction methods. Int J Pharm 353:113-123.
28. Mohamed S, Barnett SA, Tocher DA, Price SL, Shankland K, Leech CK. 2008. Discovery of three polymorphs of 7-fluoroisatin reveals challenges in using computational crystal structure prediction as a complement to experimental screening. CrystEngComm 10:399-404.
29. Aubrey-Medendorp C, Swadley MJ, Li T. 2008. The polymorphism of indomethacin: An analysis by density functional theory calculations. Pharm Res 25:953-959. (Pubitemid 351661824)
30. Wood PA, Francis D, Marshall WG, Moggach SA, Parsons S, Pidcock E, Rohl AL. 2008. A study of the high-pressure polymorphs of L-serine using ab initio structures and PIXEL calculations. CrystEngComm 10:1154-1166.
31. Bennema P, van Eupen J, van der Wolf BMA, Los JH, Meekes H. 2008. Solubility of molecular crystals: Polymorphism in the light of solubility theory. Int J Pharm 351:74-91.
32. Badawy SI, Franchini MK, Hussain MA. 2008. Salt selection for pharmaceutical compounds, Chapter 2.3. In: Adeyeye MC, Brittain HG, editors. Preformulation in solid dosage form development. New York: Informa Healthcare Press. pp 63-80.
33. Brittain HG. 2008. Preparation and identification of polymorphs and solvatomorphs, Chapter 3.3. In: Adeyeye MC, Brittain HG, editors. Preformulation in solid dosage form development. New York: Informa Healthcare Press. pp 185-228.
34. Allesø M, van den Berg F, Cornett C, Jørgensen FS, Halling-Sørensen B, Lopez de Diego H, Hovgaard L, Aaltonen J, Rantanen J. 2008. Solvent diversity in polymorph screening. J Pharm Sci 97:2145-2159.
35. Getsoian A, Lodaya RM, Blackburn AC. 2008. One-solvent polymorph screen of carbamazepine. Int J Pharm 348:3-9.
36. Mizuuchi H, Jaitely V, Murday S, Florence AT. 2008. Room temperature ionic liquids and their mixtures: Potential pharmaceutical solvents. Eur J Pharm Sci 33:326-331.
37. Cui Y, Yao E. 2008. Evaluation of hydrate-screening methods. J Pharm Sci 97:2730-2744.
38. Rodomonte A, Antoniella E, Bertocchi P, Gaudiano MC, Manna L, Bartolomei M. 2008. Different crystal morphologies arising from different preparation methods of a same polymorphic form may result in different properties of the final materials: The case of diclofenac sodium trihydrate. J Pharm Biomed Anal 48:477-481.
39. Lee S, Lee AY, Myerson AS. 2008. Concomitant polymorphism in confined environment. Pharm Res 25:960-968.
40. Lee S, Kim KT, Lee AY, Myerson AS. 2008. Concomitant crystallization of glycine on patterned substrates: The effect of pH on the polymorphic outcome. Cryst Growth Des 8:108-113.
41. Jiang S, ter Horst JG, Jansens PJ. 2008. Concomitant polymorphism of o-aminobenzoic acid in antisolvent crystallization. Cryst Growth Des 8:37-43.
42. Teychené S, Biscans B. 2008. Nucleation kinetics of polymorphs: Induction period and interfacial energy measurements. Cryst Growth Des 8:1133-1139.
43. Sun X, Garetz BA, Myerson AS. 2008. Polarization switching of crystal structure in the non-photochemical laser-induced nucleation of supersaturated aqueous L-histidine. Cryst Growth Des 8:1720-1722.
44. Murnane D, Marriott C, Martin GP. 2008. Polymorphic control of inhalation microparticles prepared by crystallization. Int J Pharm 361:141-149.
45. Tong HHY, Shekunov BY, York P, Chow AHL. 2008. Influence of operating temperature and pressure on the polymorphic transition of salmeterol xinafoate in supercritical fluids. J Pharm Sci 97:1025-1029. (Pubitemid 351293900)
46. Gong Y, Collman BM, Mehrens SM, Lu E, Miller JM, Blackburn A, Grant DJW. 2008. Stable-form screening: Overcoming trace impurities that inhibit solution-mediated phase transformation to the stable polymorph of sulfamerazine. J Pharm Sci 97:2130-2144.
47. Poornachary SK, Chow PS, Tan RBH. 2008. Influence of solution speciation of impurities on polymorphic nucleation in glycine. Cryst Growth Des 8:179-185.
48. Mohapatra H, Eckhardt CJ. 2008. Elastic constants and related mechanical properties of the monoclinic polymorph of the carbamazepine molecular crystal. J Phys Chem B 112:2293-2298.
49. Porter WW, Elie SC, Matzger AJ. 2008. Polymorphism in carbamazepine cocrystals. Cryst Growth Des 8:14-16.
50. Florence AJ, Bedford CT, Fabbiani FPA, Shankland K, Gelbrich T, Hursthouse MB, Shankland N, Johnston A, Fernandes P. 2008. Two-dimensional similarity between forms I and II of cytenamide, a carbamazepine analogue. CrystEngComm 10:811-813.
51. Suitchmezian V, Jess I, Sehnert J, Seyfarth L, Senker J, Näther C. 2008. Structural, thermodynamic, and kinetic aspects of the polymorphism and pseudopolymorphism of prednisolone (11,17a, 21-trihydroxy-1,4-pregnadien-3,20- dion). Cryst Growth Des 8:98-107.
52. Meléndez PA, Kane KM, Ashvar CS, Albrecht M, Smith PA. 2008. Thermal inkjet application in the preparation of oral dosage forms: Dispensing of prednisolone solutions and polymorphic characterization by solid-state spectroscopic techniques. J Pharm Sci 97:2619-2636.
53. Gelbrich T, Hughes DS, Hursthouse MB, Threlfall TL. 2008. Packing similarity in polymorphs of sulfathiazole. CrystEngComm 10:1328-1334.
54. Griesser UJ, Jetti RKR, Haddow MF, Brehmer T, Apperley DC, King A, Harris RK. 2008. Conformational polymorphism in oxybuprocaine hydrochloride. Cryst Growth Des 8:44-56.
55. Gelbrich T, Bingham AL, Threlfall TL, Hursthouse MB. 2008. δ-sulfanilamide. Acta Cryst C64:o205-o207.
56. Drebushchak TN, Chukanov NV, Boldyreva EV. 2008. Two polymorphs of chlorpropamide: The δ-form and the high-temperature ε-form. Acta Cryst C64:o623-o625.
57. Dudognon E, Danède F, Descamps M, Correia NT. 2008. Evidence for a new crystalline phase of racemic ibuprofen. Pharm Res 25:2853-2858.
58. Viscomi GC, Campana M, Barbanti M, Grepioni F, Polito M, Confortini D, Rosini G, Righi P, Cannata V, Braga D. 2008. Crystal forms of rifaximin and their effect on pharmaceutical properties. CrystEngComm 10:1074-1081.
59. Vogt FG, Katrincic LM, Long ST, Mueller RL, Carlton RA, Sun YT, Johnson MN, Copley RCB, Light ME. 2008. Enantiotropically- related polymorphs of {4-(4-chloro-3-fluorophenyl)-2-[4-(methyloxy)phenyl]-1,3-thiazol-5-yl} acetic acid: Crystal structures and multinuclear solid-state NMR. J Pharm Sci 97:4756-4782.
60. Maccaroni E, Alberti E, Malpezzi L, Masciocchi N, Vladiskovic C. 2008. Polymorphism of linezolid: A combined single-crystal, powder diffraction and NMR study. Int J Pharm 351:144-151. (Pubitemid 351186851)
61. Uvarov V, Popov I. 2008. Development and metrological characterization of quantitative X-ray diffraction phase analysis for the mixtures of clopidogrel bisulphate polymorphs. J Pharm Biomed Anal 46:676-682.
62. Huang J, Stringfellow TC, Yu L. 2008. Glycine exists mainly as monomers, not dimers, in supersaturated aqueous solutions: Implications for understanding its crystallization and polymorphism. J Am Chem Soc 130:13973-13980.
63. Bordallo HN, Boldyreva EV, Buchsteiner A, Koza MM, Landsgesell S. 2008. Structure-property relationships in the crystals of the smallest amino acid: An incoherent inelastic neutron scattering study of the glycine polymorphs. J Phys Chem B 112:8748-8759.
64. Reece HA, Levendis DC. 2008. Polymorphs of gabapentin. Acta Cryst C64:o105-o108.
65. van Eupen THH, Elffrink WWJ, Keltjens R, Bennema P, de Gelder R, Smits JMM, van Eck ERH, Kentgens APM, Deij MA, Meekes H, Vlieg E. 2008. Polymorphism and migratory chiral resolution of the free base of venlafaxine. A remarkable topotactical solid state transition from a racemate to a racemic conglomerate. Cryst Growth Des 8:71-79.
66. Foces-Foces C, López-Rodríguez M, Pérez C. 2008. A case of concomitant polymorphism and spontaneous resolution: The tetragonal phase of 5-hydroxymethyl-7,7,N-trimethyl-6-oxabicyclo[3.2.1] octane-1-carboxamide. Acta Cryst C64:o95-o97.
67. Parrish DA, Deschamps JR, Gilardi RD, Butcher RJ. 2008. Polymorphs of picryl bromide. Cryst Growth Des 8:57-62.
68. Barsky I, Bernstein J, Stephens PW, Stone KH, Cheung E, Hickey MB, Henck J-O. 2008. Disappearing and reappearing polymorphism in p-methylchalcone. Cryst Growth Des 8:63-70.
69. Lutker KM, Tolstyka ZP, Matzger AJ. 2008. Investigation of a privileged polymorphic motif: A dimeric ROY derivative. Cryst Growth Des 8:136-139.
70. Chandran SK, Nath NK, Roy S, Nangia A. 2008. Polymorphism in fuchsones. Cryst Growth Des 8:140-154.
71. Alberola A, Clements OP, Collis RJ, Cubbitt L, Grant CM, Less RJ, Oakley RT, Rawson JM, Reed RW, Robertson CM. 2008. Polymorphism in a π-stacked 1,3,2-dithiazolyl radical: Pyridyl-1,3,2-dithiazolyl. Cryst Growth Des 8:155-161.
72. Chopra D, Row TNG. 2008. Disorder induced concomitant polymorphism in 3-fluoro-N-(3-fluorophenyl)benzamide. Cryst Growth Des 8:848-853.
73. Guzei IA, Bikzhanova GA, Spencer LC, Timofeeva TV, Kinnibrugh TL, Campana CF. 2008. Polymorphism and history of 2-dimethylsufuranylidene-1,3-indanedione (YLID). Cryst Growth Des 8:2411-2418.
74. Bernardes CES, Piedade MFM, da Piedade MEM. 2008. Polymorphism in 4′-hydroxy acetophenone: Structure and energetics. Cryst Growth Des 8:2419-2430.
75. Hauser MR, Zhakarov L, Doxsee KM, Li T. 2008. Polymorphism of a simple organic amide. Cryst Growth Des 8:4428-4431.
76. McMullan RK, Klooster WT, Weber H-P. 2008. Deuterated γ-malonic acid: Its neutron crystal structure in relationship to other polymorphs of aliphatic dicarboxylic acids. Acta Cryst B64:230-239.
77. Gryl M, Krawczuk A, Stadnicka K. 2008. Polymorphism of urea-barbituric acid cocrystals. Acta Cryst B64:623-632.
78. Beasley AG, Welberry TR, Goossens DJ, Heerdegen AP. 2008. A room-temperature X-ray diffuse scattering study of form (II) of the trimorphic molecular system p-(N-methylbenzylidene)-p-methylaniline. Acta Cryst B64:633-643.
79. Sugiono E, Bolte M. 2008. Two polymorphs of 4-propyl-3,4-dihydro-2H- naphtho[1,2-b] pyran-5,6-dione. Acta Cryst C64: o84-o86.
80. Britton D, Noland WE, Clark CM. 2008. 5-Iodobenzofurazan 1-oxide: Polymorphs, pseudosymmetry and disorder. Acta Cryst C64:o187-o190. (Pubitemid 351502136)
81. Helliwell M, Liaaen-Jensen S, Wilkinson J. 2008. Two polymorphs of 20-desmethyl-β-carotene. Acta Cryst C64:o252-o256.
82. Zouev I, Kaftory M. 2008. Conformational dimorphism of the spiropyran 1′,3′,3′-trimethylspiro[2H-1-benzopyran-2,2′-indoline] -6-carbaldehyde). Acta Cryst C64:o372-o375.
83. van Blerk C, Kruger GJ. 2008. Hydrogen-bonding motifs and thermotropic polymorphism in redetermined halide salts of hexamethylenediamine. Acta Cryst C64:o537-o542.
84. Mazur L, Koziol AE, Modzelewska-Banachiewicz B. 2008. 2-[4-Phenyl-5-(2-pyridyl)-4H-1,2,4-triazol-3-yl]nicotinic acid: A case of solvent-dependent polymorphism. Acta Cryst C64:o574-o577.
85. Tyl A, Nowak M, Kusz J. 2008. Two polymorphs of anhydrous 4-pyridone at 100 K. Acta Cryst C64:o661-o664.
86. Brito I, Mundaca A, Cárdenas A, López-Rodríguez M. 2008. A triclinic modification of 5,50-dinitro- 2,20-dithiodipyridine. Acta Cryst E64:o102-o103.
87. Zhu L-N, Gao S, Ng SW. 2008. A monoclinic polymorph of 1,3-bis(2-pyridylamino-methyl)benzene. Acta Cryst E64: o252.
88. Jiang Z, Wang J-D, Chen N-S, Huang J-L. 2008. 2-Benzylisoindoline-1,3- dione: A monoclinic polymorph. Acta Cryst E64:o324.
89. Mague JT, Linhardt L, Medina I, Sattler DJ, Fink MJ. 2008. Monoclinic form of 1,2,4,5-tetracyclohexylbenzene. Acta Cryst E64:o375.
90. Mague JT, Linhardt L, Medina I, Sattler DJ, Fink MJ. 2008. Triclinic form of 1,2,4,5-tetracyclohexylbenzene. Acta Cryst E64:o376.
91. Jasinski JP, Butcher RJ, Yathirajan HS, Narayana B, Sreevidya TV. 2008. A second polymorph of b-arteether. Acta Cryst E64:o585-o586.
92. Kuhlmann M, Baumgartner T, Parvez M. 2008. A new polymorph of dimesitylborinic acid. Acta Cryst E64:o1185.
93. Fun H-K, Jebas SR. 2008. A second monoclinic polymorph of methyl 4-hydroxybenzoate. Acta Cryst E64:o1255.
94. Fun H-K, Franklin S, Jebas SR, Balasubramanian T. 2008. 4,4′-Dimethoxy-benzophenone: A triclinic polymorph. Acta Cryst E64:o1256.
95. Masuda JD. 2008. A monoclinic polymorph of N,N′-bis(2,6- diisopropylphenyl)-formamidine. Acta Cryst E64:o1447.
96. 3,7]decane-1-carboxamide. Acta Cryst E64:o1495.
97. Teng L, Wang Z. 2008. A polymorph of terephthalaldehyde. Acta Cryst E64:o1562.
98. Fun H-K, Chantrapromma S, Jana S, Chakrabarty R, Goswami S. 2008. A second monoclinic polymorph of 2-amino-4,6-dichloropyrimidine. Acta Cryst E64:o1659-o1660.
99. Zhu Z-F, Shen X-H, Tang X-G. 2008. A second monoclinic polymorph of 4-(2-hydroxy-4-methoxybenzylideneamino)-1,5-dimethyl-2-phenyl-1H- pyrazol-3(2H)-one. Acta Cryst E64:o1965-o1966.
100. Abdullah Z, Ng SW. 2008. A second monoclinic polymorph of N-(pyrazin-2-yl)aniline. Acta Cryst E64:o2106.
101. Abdullah Z, Ng SW. 2008. A second monoclinic modification of phenyl quinoxalin-2-yl ether. Acta Cryst E64:o2165.
102. Kharat AN, Ahmadian M, Bakhoda G, Abbasi A. 2008. Monoclinic modification of 1,2-bis(diphenylselenophosphinoyl) ethane. Acta Cryst E64:o2246.
103. Kia R, Fun H-K, Kargar H. 2008. A second monoclinic polymorph of 4,4′-[butane-1,4-diylbis(nitrilomethylidyne)]dibenzonitrile. Acta Cryst E64:o2388.
104. Kubono K, Tsuno Y, Tani K, Yokoi K. 2008. A monoclinic polymorph of 4,4′-dichloro-2,2′- (piperazine-1,4-diyldimethylene) diphenol. Acta Cryst E64:o2446.
105. Janbon S, Davey RJ, Shankland K. 2008. The crystal structure of a metastable polymorph of para-azoxyanisole. CrystEngComm 10:279-282.
106. Srivijaya R, Vishweshwar P, Sreekanth BR, Vyas K. 2008. Crystalline forms and aqueous solubilities of an IBS drug, tegaserod. CrystEngComm 10:283-287.
107. Barsky I, Bernstein J. 2008. Crystal structures and characterization of the polymorphs of (2-furyl) oxoacetamide. CrystEngComm 10:669-674.
108. Evans IR, Howard JAK, Evans JSO, Postlethwaite SR, Johnson MR. 2008. Polymorphism and hydrogen bonding in cinchomeronic acid: A variable temperature experimental and computational study. CrystEngComm 10:1404-1409.
109. Harada J, Harakawa M, Ogawa K. 2008. Conformational change of all-trans-1,6-diphenyl-1,3,5-hexatriene in two crystalline forms. CrystEngComm 10:1777-1781.
110. 13C high-resolution solid-state NMR study of the polymorphism of the L-enantiomer of N-benzoylphenylalanine. J Phys Chem B 112:1586-1593.
111. Côte M, Hughes CE, Austin TK, Rogueda PGA, Pan Z, Harris KDM, Griffiths PC. 2008. Characterization of a polymorphic system exhibiting substantial variation of solubility in a fluorinated solvent. J Phys Chem C 112:14570-14578.
112. Johnston A, Johnston BF, Kennedy AR, Florence AJ. 2008. Targeted crystallization of novel carbamazepine solvates based on a retrospective Random Forest classification. CrystEngComm 10:23-25.
113. Johnston A, Florence AJ, Fabbiani FJA, Shankland K, Bedford CT, Bardin J. 2008. Cytenamide trifluoroacetic acid solvate. Acta Cryst E64:o1215-o1216.
114. Johnston A, Florence AJ, Fabbiani FJA, Shankland K, Bedford CT. 2008. Cytenamide 1,4-dioxane (2/1). Acta Cryst E64:o1345-o1346.
115. Harris RK, Hodgkinson P, Larsson T, Muruganantham A, Ymén I, Yufit DS, Zorin V. 2008. Characterization of polymorphs and solvates of terbutaline sulfate. Cryst Growth Des 8:80-90.
116. Braun DE, Kahlenberg V, Gelbrich T, Ludescher J, Griesser UJ. 2008. Solid state characterization of four solvates of R-cinacalcet hydrochloride. CrystEngComm 10:1617-1625.
117. Maccaroni E, Alberti E, Malpezzi L, Masciocchi N, Pellegatta C. 2008. Crystal chemistry of sibutramine: Thermal, diffractometric and spectroscopic characterization. J Pharm Sci 97:5229-5239.
118. Suitchmezian V, Jess I, Näther C. 2008. Structural, thermodynamic, and kinetic aspects of the trimorphism of hydrocortisone. J Pharm Sci 97:4516-4527.
119. Chen J, Wang J, Ulrich J, Yin Q, Xue L. 2008. Effect of solvent on the crystal structure and habit of hydrocortisone. Cryst Growth Des 8:1490-1494.
120. Llinàs A, Burley JC, Prior TJ, Glen RC, Goodman JM. 2008. Concomitant hydrate polymorphism in the precipitation of sparfloxacin from aqueous solution. Cryst Growth Des 8:114-118.
121. Roy S, Goud NR, Babu NJ, Iqbal J, Kruthiventi AK, Nangia A. 2008. Crystal structures of norfloxacin hydrates. Cryst Growth Des 8:4343-4346.
122. Caira MR, Stieger N, Liebenberg W, De Villiers MM, Samsodien H. 2008. Solvent inclusion by the anti-HIV drug nevirapine: X-ray structures and thermal decomposition of representative solvates. Cryst Growth Des 8:17-23.
123. da Silva CCP, Cuffini SL, Faudone SN, Ayala AP, Ellena J. 2008. Low-temperature study of a new nevirapine pseudopolymorph. Acta Cryst E64:o292.
124. Yoshioka S, Aso Y, Osako T, Kawanishi T. 2008. Wide-ranging molecular mobilities of water in active pharmaceutical ingredient (API) hydrates as determined by NMR relaxation times. J Pharm Sci 97:4258-4268.
125. Kojima T, Yamauchi Y, Onoue S, Tsuda Y. 2008. Evaluation of hydrate formation of a pharmaceutical solid by using diffuse reflectance infrared Fourier-transform spectroscopy. J Pharm Biomed Anal 46:788-791.
126. Kauffman JF, Tumuluri V, Guo C, Spencer JA, Doub WH, Nichols GA, Randle SR, Wu S. 2008. Near infrared spectroscopy of magnesium stearate hydrates and multivariate calibration of pseudopolymorph composition. J Pharm Sci 97:2757-2767.
127. Kojima T, Sugano K, Onoue S, Murase N, Sato M, Kawabata Y, Mano T. 2008. Solid form selection of zwitterionic 5-HT4 receptor agonist. Int J Pharm 350:35-42.
128. Tong HHY, Wu HB, Zheng Y, Xi J, Chow AHL, Chan CK. 2008. Physical characterization of oleanolic acid nonsolvate and solvates prepared by solvent recrystallization. Int J Pharm 355:195-202.
129. Braun DE, Gelbrich T, Jetti RKR, Kahlenberg V, Price SL, Griesser UJ. 2008. Colored polymorphs: Thermochemical and structural features of N-picryl-p-toluidine polymorphs and solvates. Cryst Growth Des 8:1977-1989.
130. Mondal R, Howard JAK. 2008. A structural investigation of six solvates of trans-1,4-Bis(phenylethynyl)-cyclohexane-1,4-diol. Cryst Growth Des 8:4359-4366.
131. Laus G, Kahlenberg V, Wurst K, Lörting T, Schottenberger H. 2008. Hydrogen bonding in the perhydrate and hydrates of 1,4-diazabicyclo[2.2.2]- octane (DABCO). CrystEngComm 10:1638-1644.
132. Janik A, Jarocha M, Stadnicka K. 2008. Pseudopolymorphism of N-acetyl-L-phenylalanine methyl ester. Acta Cryst B64:223-229.
133. Cuffini SL, Faudone S, Ferro M, Garland MT, Baggio R. 2008. Rosiglitazone maleate 0.25-hydrate: A pseudopolymorphic form. Acta Cryst C64:o119-o122.
134. Görbitz CH, Hartviksen LM. 2008. The monohydrates of the four polar dipeptides L-seryl-L-asparagine, L-seryl-L-tyrosine, L-tryptophanyl-L-serine and L-tyrosyl-L-tryptophan. Acta Cryst C64:o171-o176.
135. Venu N, Sreekanth BR, Ram T, Devarakonda S. 2008. Desvenlafaxine succinate monohydrate. Acta Cryst C64:o290-o292.
136. Xu X-M, Su P, Meng X-G. 2008. A new polymorph of 1,4- bis(imidazol-1-yl-methyl)benzene dihydrate and its hydrogen-bonded fivefold interpenetrated CdSO4 network. Acta Cryst C64:o675-o678.
137. Yang Q, Ye W-D, Yuan J-Y, Nie J-J, Xu D-J. 2008. Eplerenone ethanol solvate. Acta Cryst E64:o829.
138. Silva PSP, Domingos SR, Silva MR, Paixão JA, Beja AM. 2008. A new polymorph of 5-nitrouracil monohydrate. Acta Cryst E64:o1091.
139. Johnston A, Florence AJ, Kennedy AR. 2008. Chlorothiazide-pyridine (1/3). Acta Cryst E64:o1105-o1106.
140. Tan S-K, Osman H, Wong K-C, Fun H-K, Chantrapromma S. 2008. Swietenolide monohydrate. Acta Cryst E64:o1267-o1268.
141. Liang J-H, Yao G-W. 2008. A new crystal structure of clarithromycin. J Chem Crystallogr 38:61-64.
142. Nagase H, Ogawa N, Endo T, Shiro M, Ueda H, Sakurai M. 2008. Crystal structure of an anhydrous form of trehalose: Structure of water channels of trehalose polymorphism. J Phys Chem B 112:9105-9111.
143. Kachrimanis K, Fucke K, Noisternig M, Siebenhaar B, Griesser UJ. 2008. Effects of moisture and residual solvent on the phase stability of orthorhombic paracetamol. Pharm Res 25:1440-1449.
144. Barthe SC, Grover MA, Rousseau RW. 2008. Observation of polymorphic change through analysis of FBRM data: Transformation of paracetamol from Form II to Form I. Cryst Growth Des 8:3316-3322.
145. Jia C-Y, Yin Q-X, Zhang M-J, Wang J-K, Shen Z-H. 2008. Polymorphic transformation of pravastatin sodium monitored using combined online FBRM and PVM. Org Process Res Dev 12:1223-1228.
146. Manduva R, Kett VL, Banks SR, Wood J, Reading M, Craig DQM. 2008. Calorimetric and spatial characterization of polymorphic transitions in caffeine using quasi-isothermal MTDSC and localized thermomechanical analysis. J Pharm Sci 97:1285-1300.
147. Kim H-J, Kim K-J. 2008. In situ monitoring of polymorph transformation of clopidogrel hydrogen sulfate using measurement of ultrasonic velocity. J Pharm Sci 97:4473-4484.
148. Lehto P, Aaltonen J, Niemelä P, Rantanen J, Hirvonen J, Tanninen VP, Peltonen L. 2008. Simultaneous measurement of liquid-phase and solid-phase transformation kinetics in rotating disc and channel flow cell dissolution devices. Int J Pharm 363:66-72.
149. Cornel J, Lindenberg C, Mazzotti M. 2008. Quantitative application of in situ ATR-FTIR and Raman spectroscopy in crystallization processes. Ind Eng Chem Res 47:4870-4882.
150. Cornel J, Mazzotti M. 2008. Calibration-free quantitative application of in situ Raman Spectroscopy to a crystallization process. Anal Chem 80:9240-9249.
151. ter Horst JH, Cains PW. 2008. Cocrystal polymorphs from a solvent-mediated transformation. Cryst Growth Des 8:2537-2542.
152. Lee EH, Boerrigter SXM, Rumondor ACF, Chamarthy SP, Byrn SR. 2008. Formation and solid-state characterization of a salt-induced metastable polymorph of flufenamic acid. Cryst Growth Des 8:91-97.
153. Chongcharoen W, Byrn SR, Sutanthavibul N. 2008. Solid state interconversion between anhydrous norfloxacin and its hydrates. J Pharm Sci 97:473-489.
154. Khawam A, Flanagan DR. 2008. Desolvation kinetics of sulfameter solvates. J Pharm Sci 97:2160-2175.
155. Guguta C, Meekes M, de Gelder R. 2008. The hydration/dehydration behavior of aspartame revisited. J Pharm Biomed Anal 46:617-624.
156. Bhugra C, Pikal MJ. 2008. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci 97:1329-1349.
157. Tombari E, Ferrari C, Johari GP, Shanker RM. 2008. Calorimetric relaxation in pharmaceutical molecular glasses and its utility in understanding their stability against crystallization. J Phys Chem B 112:10806-10814.
158. Bhugra C, Shmeis R, Pikal MJ. 2008. Role of mechanical stress in crystallization and relaxation behavior of amorphous indomethacin. J Pharm Sci 97:4446-4458.
159. Marsac PJ, Konno H, Rumondor ACF, Taylor LS. 2008. Recrystallization of nifedipine and felodipine from amorphous molecular level solid dispersions containing poly(vinylpyrrolidone) and sorbed water. Pharm Res 25:647-656. (Pubitemid 351357733)
160. Jones MD, Beezer AE, Buckton B. 2008. Determination of outer layer and bulk dehydration kinetics of trehalose dihydrate using atomic force microscopy, gravimetric vapour sorption and near infrared spectroscopy. J Pharm Sci 97:4404-4415.
161. Tsekova DS, Escuder B, Miravet JF. 2008. Solid-state polymorphic transition and solvent-free self-assembly in the growth of organic crystalline microfibers. Cryst Growth Des 8:11-13.
162. Ueno S, Nishida T, Sato K. 2008. Synchrotron radiation microbeam X-ray analysis of microstructures and the polymorphic transformation of spherulite crystals of trilaurin. Cryst Growth Des 8:751-754.
163. Trevor SL, Butler MF, Adams S, Laity PR, Burley JC, Cameron RE. 2008. Structure and phase transitions of genipin, an herbal medicine and naturally occurring cross-linker. Cryst Growth Des 8:1748-1753.
164. Dharmayat S, Hammond RB, Lai X, Ma C, Purba E, Roberts KJ, Chen Z-P, Martin E, Morris J, Bytheway R. 2008. An examination of the kinetics of the solution-mediated polymorphic phase transformation between α- and β-Forms of L-glutamic acid as determined using online powder X-ray diffraction. Cryst Growth Des 8:2205-2216.
165. Harings JAW, van Asselen O, Graf R, Broos R, Rastogi S. 2008. The role of superheated water on the crystallization of N,N′-1,2-ethanediyl-bis(6- hydroxy-hexanamide): Implications on crystallography and phase transitions. Cryst Growth Des 8:2469-2477.
166. Gonnade RG, Bhadbhade MM, Shashidhar MS. 2008. Crystalto-crystal transformation amongst dimorphs of racemic 2,6-di-O-(p-halo benzoyl)-myo- inositol 1,3,5-orthoformates that achieves halogen bonding contacts. CrystEngComm 10:288-296.
167. Howard JAK, Sparkes HA. 2008. Trans-4-(trifluoromethyl) cinnamic acid: Structural characterisation and crystallographic investigation into the temperature induced phase transition. CrystEngComm 10:502-506.
168. Johnstone RDL, Francis D, Lennie AR, Marshall WG, Moggach SA, Parsons S, Pidcock E, Warren JE. 2008. High-ressure polymorphism in L-serine monohydrate: Identification of driving forces in high pressure phase transitions and possible implications for pressure-induced protein denaturation. CrystEngComm 10:1758-1769.
169. Beckham GT, Peters B, Trout BL. 2008. Evidence for a size dependent nucleation mechanism in solid state polymorph transformations. J Phys Chem B 112:7460-7466.
170. Minkov VS, Krylov AS, Boldyreva EV, Goryainov SV, Bizyaev SN, Vtyurin AN. 2008. Pressure-induced phase transitions in crystalline L- and DL-cysteine. J Phys Chem B 112:8851-8854.
171. Nieuwendaal RC, Bertmer M, Hayes SE. 2008. An unexpected phase transition during the [2 + 2] photocycloaddition reaction of cinnamic acid to truxillic acid: Changes in polymorphism monitored by solid-state NMR. J Phys Chem B 112:12920-12926.
172. Agatonovic-Kustrin S, Glass BD, Smithson MMJ. 2008. Analyzing the crystal purity of mebendazole raw material and its stability in a suspension formulation. Int J Pharm 361:245-250.
173. Kojima T, Katoh F, Matsuda Y, Teraoka R, Kitagawa S. 2008. Physicochemical properties of tamoxifen hemicitrate sesquihydrate. Int J Pharm 352:146-151.
174. Kelmann RG, Kuminek G, Teixeira HF, Koester LS. 2008. Preliminary study on the development of nanoemulsions for carbamazepine intravenous delivery: An investigation of drug polymorphic transition. Drug Dev Ind Pharm 34:53-58.
175. Gift AD, Luner PE, Luedeman L, Taylor LS. 2008. Influence of polymeric excipients on crystal hydrate formation kinetics in aqueous slurries. J Pharm Sci 97:5198-5211.
176. Wikström H, Carroll WJ, Taylor LS. 2008. Manipulating theophylline monohydrate formation during high-shear wet granulation through improved understanding of the role of pharmaceutical excipients. Pharm Res 25:923-935. (Pubitemid 351661841)
177. Német Z, Sztatisz J, Demeter A. 2008. Polymorph transitions of bicalutamide: A remarkable example of mechanical activation. J Pharm Sci 97:3222-3232.
178. Cheng W-T, Lin S-Y. 2008. Famotidine polymorphic transformation in the grinding process significantly depends on environmental humidity or water content. Int J Pharm 357:164-168.
179. De Gusseme A, Neves C, Willart JF, Rameau A, Descamps M. 2008. Ordering and disordering of molecular solids upon mechanical milling: The case of fananserine. J Pharm Sci 97:5000-5012.
180. Feng T, Pinal R, Carvajal MT. 2008. Process induced disorder in crystalline materials: Differentiating defective crystals from the amorphous form of griseofulvin. J Pharm Sci 97:3207-3221.
181. Cheng W-T, Lin S-Y, Wang S-L. 2008. Differential scanning calorimetry with curve-fitting program used to quantitatively analyze the polymorphic transformation of famotidine in the compressed compact. Drug Dev Ind Pharm 34:1368-1375.
182. Joiris E, Di Martino P, Malaj L, Censi R, Barthélémy C, Odou P. 2008. Influence of crystal hydration on the mechanical properties of sodium naproxen. Eur J Pharm Biopharm 70:345-356.
183. Konno H, Taylor LS. 2008. Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture. Pharm Res 25:969-978.
184. Betigeri S, Thakur A, Shukla R, Raghavan K. 2008. Effect of polymer additives on the transformation of BMS-566394 anhydrate to the dihydrate form. Pharm Res 25:1043-1051. (Pubitemid 351521104)
185. Xie Y, Cao W, Krishnan S, Lin H, Cauchon N. 2008. Characterization of mannitol polymorphic forms in lyophilized protein formulations using a multivariate curve resolution (MCR)-based Raman spectroscopic method. Pharm Res 25:2292-2301.
186. Schneid S, Riegger X, Gieseler H. 2008. Influence of common excipients on the crystalline modification of freeze-dried mannitol. Pharm Tech 32:178-184.
187. Shah KR, Hussain MA, Hubert M, Badawy SIF. 2008. Form conversion of anhydrous lactose during wet granulation and its effect on compactibility. Int J Pharm 357:228-234.
188. Listiohadi Y, Hourigan JA, Sleigh RW, Steele RJ. 2008. Moisture sorption, compressibility and caking of lactose polymorphs. Int J Pharm 359:123-134.
189. Tantishaiyakul V, Permkam P, Suknuntha K. 2008. Use of drifts and PLS for the determination of polymorphs of piroxicam alone and in combination with pharmaceutical excipients. AAPS PharmSciTech 9:95-99.
190. Chierotti MR, Gobetto R, Pellegrino L, Milone L, Venturello P. 2008. Mechanically induced phase change in barbituric acid. Cryst Growth Des 8:1454-1457.
191. Myerson AS, Lee AY. 2008. Method for producing crystals and screening crystallization conditions. United States patent 7,329,319: February 12, 2008.
192. Matzger AJ, Lang M, Kim K. 2008. Systems and methods for the generation of crystalline polymorphs. United States patent 7,429,238: September 30, 2008.
193. Neiss JH, Treado PJ, Schweitzer R. 2008. System and method for spectral unmixing in a fiber array spectral translator based polymorph screening system. United States patent 7,471,386: December 30, 2008.
194. Tuschel D, Treado PJ, Nelson MP. 2008. System and method for fiber array spectral translator based polymorph screening. United States patent 7,471,389: December 30, 2008.
195. Aronhime J, Lidor-Hadas R, Niddam V, Lifshitz R, Wizel S. 2008. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms. United States patent 7,342,120: March 11, 2008.
196. Tessler L, Aronhime J, Lifshitz-Liron R, Maidan-Hanoch D, Hasson N. 2008. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms. United States patent 7,456,297: November 25, 2008.
197. Aronhime J, Lidor-Hadas R, Niddam V, Lifshitz R, Wizel S. 2008. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms. United States patent 7,468,444: December 23, 2008.
198. Lifshitz-Liron R, Koltai T, Aronhime J, Perlman N. 2008. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them. United States patent 7,368,468: May 6, 2008.
199. Lifshitz-Liron R, Koltai T, Aronhime J, Perlman N, Avhar- Maydan S. 2008. Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them. United States patent 7,414,140: August 19, 2008.
200. Rao DR, Kankan RN, Gangrade MG, Birari DR. 2008. Fexofenadine polymorphs and processes of preparing the same. United States patent 7,470,789: December 30, 2008.
201. Garti N, Berkovich Y, Dolitzky B-Z, Aronhime J, Singer C, Liebermann A, Gershon N. 2008. Crystal forms of lamotrigine and processes for their preparations. United States patent 7,390,807: June 24, 2008.
202. Merli V, Mantovani S, Bianchi S, Daverio P, Spreafico A, Aronhime J, Kovacsne-Mezei A. 2008. Levalbuterol hydrochloride Polymorph A. United States patent 7,465,831: December 16, 2008.
203. Auffret AD, Fitzgerald MP. 2008. Process for controlling the hydrate mix of a compound. United States patent 7,323,572: January 29, 2008.
204. Dolitzky BZ, Aronhime J, Diller D. 2008. Crystal forms, methods for their preparation and method for preparation of olanzapine. United States patent 7,323,459: January 29, 2008.
205. Gyollai V, Szabo C, Singer C, Amir E. 2008. Aztreonam β polymorph with very low residual solvent content. United States patent 7,452,991: November 18, 2008.
206. Greenwood AK, McHattie D, Bhatarah P, Aloui M. 2008. Preparation of cabergoline. United States patent 7,339,060: March 4, 2008.
207. Kawazoe S, Sakamoto K, Awamura Y, Maruyama T, Suzuki T, Onda K, Takasu T. 2008. α-form or β-form crystal of acetanilide derivative. United States patent 7,342,117: March 11, 2008.
208. Tanoury GJ, Senanayake CH, Kessler DW. 2008. Formoterol tartrate process and polymorph. United States patent 7,342,132: March 11, 2008.
209. Hayashi T, Kawakami T, Iwanaga Y, Watanabe Y. 2008. Crystal and solvate of 2-amino-6-benzyloxypurine and production methods thereof. United States patent 7,345,170: March 18, 2008.
210. Blackler PDJ, Giles RG, Moore S, Sasse MJ. 2008. Thiazolidinedione derivative and its use as antidiabetic. United States patent 7,358,366: April 15, 2008.
211. Iwai M, Nakamura K, Dohi M, Mochizuki H, Mochizuki S. 2008. Solid preparation containing single crystal form. United States patent 7,361,676: April 22, 2008.
212. Tan L, Meissner RS, Li W, Perkins JJ, Cote AS, Stellabott J, Kiang Y-H. 2008. Polymorphs of an androgen receptor modulator. United States patent 7,365,202: April 29, 2008.
213. Reddy BP, Reddy KR, Reddy RR, Reddy DM, Reddy KSC. 2008. Polymorphs of tolterodine tartrate. United States patent: July 1, 2008.
214. Ini S, Liberman A, Koltai T. 2008. Crystal forms of (S)-(+)-N,N-dimethyl- 3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine oxalate and the preparation thereof. United States patent 7,399,871: July 15, 2008.
215. Wang G, Lu X, Liu Q, Tang Y, Yang L. 2008. Crystal form of adefovir dipivoxil and its preparation. United States patent 7,417,036: August 26, 2008.
216. Bombarda C, Dubini E, Ezhaya A, Schneider M, Schneider H. 2008. Stable polymorph of flibanserin. United States patent 7,420,057: September 2, 2008.
217. Bhandarkar S, Majuru S, Levchik H. 2008. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate. United States patent 7,420,085: September 2, 2008.
218. Tong W, Tadayon A, Larkin PJ, Krishnan L, Deshmukh SS, Akin JM. 2008. Crystalline polymorphs of (3S)-N-hydroxy-4-({4-[-(4-hydroxy-2-butynyl)oxy] phenyl} sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide. United States patent 7,435,732: October 14, 2008.
219. Chen S-P, Harn P-J. 2008. Crystal forms of irinotecan hydrochloride. United States patent 7,435,818: October 14, 2008.
220. Loebermann H, Caster K-H. 2008. Hydrates of optionally substituted 2-(2-pyridinyl) methylthio-1H-benzimidazoles and process for the production thereof. United States patent 7,435,825: October 14, 2008.
221. Aronhime J, Lifshitz-Liron R. 2008. Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation. United States patent 7,435,827: October 14, 2008.
222. Deshmukh SS. 2008. CCI-779 polymorph and use thereof. United States patent 7,442,707: October 28, 2008.
223. Sun C, Foster TP, Han F, Hawley M, Thamann T. 2008. Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors. United States patent 7,452,913: November 18, 2008.
224. Miller TA, Richon VM, Chiao JH. 2008. Polymorphs of suberoylanilide hydroxamic acid. United States patent 7,456,219: November 25, 2008.
225. Zook SE, Hettinger D, DuBois HR. 2008. Polymorph of N-methyl-N-(3-{3-[2- thienylcarbonyl]-pyrazol-[1,5-a]-pyrimidin-7-yl-}phenyl)acetamide and compositions and methods related thereto. United States patent 7,459,458: December 2, 2008.
226. Bhandarkar S, Majuru S, Levchik H. 2008. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino]butanoate. United States patent 7,462,368: December 9, 2008.
227. Merli V, Daverio P, Kovacsne-Mezei A, Aronhime J. 2008. Polymorphs of memantine hydrochloride. United States patent 7,462,743: December 9, 2008.